Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of a clinician reviewing implantable glucose sensor technology and digital blood glucose trends, as Glucotrack seeks FDA approval to begin a U.S. clinical study of its continuous blood glucose monitoring system.
Medical Devices & Diagnostics

Why Glucotrack’s CBGM filing could test the next frontier in diabetes monitoring

Wearable CGMs dominate diabetes care. Glucotrack’s implantable CBGM now faces the harder FDA test: durable blood-based proof.

Read More
Representative image: AI-enabled musculoskeletal ultrasound imaging in a clinical setting, highlighting how Rivanna’s FDA-cleared Accuro XV system could support point-of-care assessment of bone and soft-tissue injuries.
Medical Devices & Diagnostics

How Rivanna’s Accuro XV could change hospital imaging workflows after FDA clearance

X-rays dominate fracture triage. Rivanna’s FDA-cleared Accuro XV tests whether ultrasound can move closer to the front line.

Read More
Representative image of a noninvasive abdominal sensor used in a clinical bladder function assessment, highlighting how Bright Uro’s FDA-cleared Glean Abdominal Sensor could support catheter-free urodynamics and real-world evaluation of bladder dysfunction.
Medical Devices & Diagnostics

Can Bright Uro’s new sensor finally make bladder testing less uncomfortable?

Bladder testing needs better real-world data. Bright Uro’s FDA-cleared sensor may push urodynamics beyond catheter-heavy workflows.

Read More
Representative image: A clinician reviews pelvic imaging and biomarker data in a women’s health diagnostics setting, reflecting how non-invasive endometriosis tests using saliva, blood and molecular imaging could help shorten years-long diagnosis delays.
Features & Analysis

Is endometriosis diagnosis finally moving beyond surgery after years of missed symptoms?

Endometriosis testing is escaping the surgery-first era. Saliva, blood and imaging tools now face the harder test: clinical utility.

Read More
Representative image: Angelini Pharma’s $4.1 billion Catalyst Pharmaceuticals acquisition highlights the growing race for rare disease and neurology assets, with Firdapse, Agamree and U.S. commercial scale at the center of the deal.
Pharma & Biotech

Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals

Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.

Read More
Representative image of a modern U.S. pharmaceutical manufacturing campus, highlighting how Eli Lilly’s $4.5 billion Indiana expansion could strengthen domestic drug production capacity for obesity, diabetes and advanced genetic medicines.
Pharma & Biotech

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.

Read More
Representative image: GSK’s $1 billion SiranBio deal highlights how oligonucleotide therapies such as SA030 could open a new front in metabolic disease research by targeting visceral fat biology beyond conventional obesity drugs.
Pharma & Biotech

GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery

GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.

Read More
Representative image of an AI-enabled autonomous biopharma lab, where robotic systems, automated assays and data-driven workflows are reshaping how researchers design experiments and accelerate drug discovery.
Features & Analysis

Are autonomous labs quietly turning biopharma researchers into scientific strategists?

Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.

Read More
Representative image of AI-powered digital pathology and oncology biomarker analysis, illustrating how Daiichi Sankyo and Waiv’s ADC collaboration could support smarter patient selection in precision cancer drug development.
Pharma & Biotech

Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials

ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More